【私募调研记录】盘京投资调研迈威生物

Group 1 - The core viewpoint of the news is that Panjing Investment has conducted research on Maiwei Biotech, focusing on its collaboration with Calico to accelerate the clinical validation and commercialization of IL-11 monoclonal antibody (MW38) in anti-aging and fibrosis-related fields [1] - Maiwei Biotech's IL-11 monoclonal antibody has shown mechanisms of action in anti-aging and anti-fibrosis, with Calico interested in its potential for extending healthy lifespan [1] - MW38 has received clinical access approvals in China, the US, and Australia, with Phase I clinical trials completed in China and Australia, and preparations underway for the US clinical trials [1] Group 2 - Panjing Investment, established in 2016, is recognized as one of China's leading private equity fund managers, focusing on investment opportunities in Chinese listed companies and having a broad layout in overseas markets, especially in Chinese concept stocks [2] - The company emphasizes research-driven investment decisions, building a leading internal research team and maintaining strong relationships with top brokerage research institutes in China [2] - Panjing Investment aims to create long-term sustainable returns for clients by leveraging deep industry and individual stock research, along with solid value judgments to navigate different market cycles [2]